CardioNet, Inc. Announces Clinical Study Supporting The Efficacy Of CardioNet MCOTTM In Detecting Atrial Fibrillation In Cryptogenic Stroke Patients

CardioNet, Inc. (NASDAQ:BEAT), the leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, today announced the publication of a new clinical study that further supports CardioNet’s Mobile Cardiac Outpatient Telemetry (MCOT TM) in detecting a high rate of atrial fibrillation in cryptogenic stroke.

This new study, titled “Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke,” was authored by Daniel J Miller, MD, et al, Henry Ford Hospital, Department of Neurology, and was published online on October 24th in the Journal of the Neurological Sciences. The study showed that MCOT TM frequently detects paroxysmal atrial fibrillation in patients with cryptogenic stroke and transient ischemic attack (TIA). This study is confirmation of the value of MCOT TM for monitoring patients with cryptogenic stroke and TIA for atrial fibrillation, one potential and treatable, cause of stroke.

Dr. Miller, senior author of the study, commented: “This study highlights the importance of a standardized approach to the evaluation for potential arrhythmias in patients with cryptogenic stroke or TIA. Screening with a minimum of 21 days of outpatient telemetry monitoring with automated arrhythmia detection software should be considered a routine part of the stroke evaluation in these patients. Identification and treatment of atrial fibrillation in these patients will likely reduce the risk of future stroke.”

Joseph Capper, President and Chief Executive Officer of CardioNet commented: “I would like to thank Dr. Miller for his excellent work on this study, which serves as yet another validation of the many benefits of incorporating CardioNet’s MCOT TM into the care protocol for a variety of different at-risk patients; in this case, for patients with cryptogenic stroke and TIA. This study supplements the extensive portfolio of clinical papers and abstracts supporting the capabilities and clinical efficacy of the MCOT TM technology.”

This recent clinical trial supports the results from a previous study, “Atrial Fibrillation Detected by Mobile Cardiac Outpatient Telemetry in Cryptogenic TIA or Stroke”, authored by A.H. Tayal, M.D. et al, Allegheny General Hospital, Comprehensive Stroke Center and published in the November 18, 2008 issue of Neurology which concluded that the CardioNet MCOT TM detected a high rate of atrial fibrillation in patients that have experienced a TIA or stroke.

About CardioNet

CardioNet is a leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual’s health. CardioNet’s initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient Telemetry TM (MCOT TM). More information can be found at http://www.cardionet.com.

Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in the Company’s future. These statements may be identified by words such as “expect,” “may,” “anticipate,” “possible,” “estimate,” “potential,” “intend,” “plan,” “believe,” “forecast,” “promises” and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effectiveness of our efforts to address operational initiatives, including cost savings initiatives that affect our business, changes to insurance coverage, relationships with our government and commercial payors and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services and patent protection, adverse regulatory action and litigation success. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Copyright Business Wire 2010

If you liked this article you might like

Delta Air Lines, BioTelemetry, TransUnion: 'Mad Money' Lightning Round

Delta Air Lines, BioTelemetry, TransUnion: 'Mad Money' Lightning Round

Are Stocks Cheaper Than We Think?: Cramer's 'Mad Money' Recap (Tues 10/17/17)

Are Stocks Cheaper Than We Think?: Cramer's 'Mad Money' Recap (Tues 10/17/17)

BioTelemetry: Cramer's Top Takeaways

BioTelemetry: Cramer's Top Takeaways

Beware This Bull Stampede: Cramer's 'Mad Money' Recap (Tuesday 10/3/17)

Beware This Bull Stampede: Cramer's 'Mad Money' Recap (Tuesday 10/3/17)

Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap (Mon 9/25/17)

Rocket Stocks Look Better on Re-Entry: Cramer's 'Mad Money' Recap (Mon 9/25/17)